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ABSTRACT  The metabolic fate of anthocyanins until recently was relatively unknown, primarily 1 
as a result of their instability at physiological pH and a lack of published methods for isolating and 2 
identifying their metabolites from biological samples. The aim of the present work was to establish 3 
methods for the extraction and quantification of anthocyanin metabolites present in urine, serum and 4 
fecal samples. 35 commercial and 10 synthetic analytes, including both known and predicted human 5 
and microbial metabolites of anthocyanins were obtained as reference standards. HPLC and MS/MS 6 
conditions were optimized for organic modifier, ionic modifier, mobile phase gradient, flow rate, 7 
column type and MS source and compound dependent parameters. The impact of sorbent, solvent, 8 
acid, preservative, elution and evaporation on SPE extraction efficiency was also explored. The 9 
HPLC-MS/MS method validation demonstrated acceptable linearity (r2, 0.997 ± 0.002) and sensitivity 10 
(LODs: urine, 100 ± 375 nM; serum, 104 ± 358 nM and feces 138 ± 344 nM) and the final SPE 11 
methods provided recoveries of 88.3 ± 17.8% for urine, 86.5 ± 11.1% for serum and 80.6 ± 20.9% for 12 
feces. Final methods were applied to clinical samples derived from an anthocyanin intervention study, 13 
where 36 of the 45 modeled metabolites were detected within urine, plasma or fecal samples. The 14 
described methods provide suitable versatility for the identification and quantification of an extensive 15 
series of anthocyanin metabolites for use in future clinical studies exploring absorption, distribution, 16 
metabolism and elimination.17 
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Introduction 1 
Epidemiological evidence suggests an association between the consumption of foods rich 2 
in anthocyanins and a decreased risk of cardiovascular disease 1-3. However, until recently 3 
there was a considerable lack of information regarding the bioavailability and metabolic fate 4 
of anthocyanins in humans 4,5. A limited number of previous human studies have reported the 5 
degradation of anthocyanins into phenolic acids and aldehydes and their subsequent methyl, 6 
glucuronide and sulfate conjugation, yet there are still conflicting reports in the literature 7 
regarding the identity and prevalence of the major metabolites present following the 8 
consumption of anthocyanin-rich foods 4-10. 9 
The major challenges associated with the recovery and detection of anthocyanins relate to 10 
their instability under neutral pH 11, their extensive metabolic conjugation in vivo 12 and their 11 
probable catabolism by intestinal microflora 13. It is therefore likely that after consumption of 12 
anthocyanin rich foods, a complex mixture of intact anthocyanins, phenolic degradation 13 
products, phase II metabolic conjugates and colonic metabolites exist in tissues and 14 
biological fluids 4. Whilst a number of methods have been developed for the analysis of 15 
flavonoids and flavonoid derived phenolics 14-16, the vast majority of reported methods for 16 
anthocyanin analysis (in particular) have concentrated on quantification of parent/precursor 17 
forms or their respective metabolic conjugates (methyl, glucuronide and sulfate derivatives of 18 
anthocyanins). There are limited reports where quantitative analytical methods have been 19 
optimized for the analysis of anthocyanins and their phenolic acid and aldehyde degradation 20 
products and metabolites together 9,13,17. Understandably, developing an appropriate method 21 
for this purpose presents many challenges, as there is an extremely large diversity of 22 
metabolic by-products whose structures and physicochemical properties make extraction and 23 
quantification in complex matrices problematic. In addition, many phase II conjugates of 24 
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phenolic acids are not commercially available for use as reference standards. In order to 1 
facilitate development of a suitable method, in-house synthesis is often necessary.  2 
The objective of the present study was to ultimately validate methods suitable for 3 
determining the absorption, distribution, metabolism and elimination (ADME) of 4 
anthocyanins, including the clearance of their degradation products and metabolites in 5 
clinical samples. In addition, HPLC and MS variables such as organic modifier, ionic 6 
modifier concentration, mobile phase gradient, flow rate, column, ion source and multiple 7 
reaction monitoring (MRM) parameters were optimized to increase analytical performance. 8 
Analytical methods were validated for linearity, precision and accuracy using the U.S. 9 
Department of Health and Human Services Food and Drug Administration (FDA) guidance 10 
for industry bioanalytical methods validation 18, for the 45 analytes and confirmed using 11 
clinically derived urine, serum and fecal samples. The analytes explored include 12 
anthocyanins, their degradation products, phase II conjugates and probable colonic 13 
metabolites 13 (Supplementary Information Table 1). As many factors can influence 14 
analyte recoveries in biological matrices, the present study also aimed to validate the impact 15 
of several commonly utilized variables (i.e., sorbent, solvent, acid type, preservative, elution 16 
and sample evaporation) 19-28 on the extraction efficiency by solid phase extraction (SPE) of 17 
the 45 analytes spiked into biological matrices (urine, serum and fecal homogenate). The 18 
present study therefore describes methods for the identification and quantification of an 19 
extensive series of anthocyanin metabolites and the validation of these methods demonstrates 20 
suitability for use in future clinical intervention studies.  21 
 22 
Experimental 23 
Materials and reagents 24 
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Strata-X™ SPE cartridges (6 mL, 500 mg, 88 Å),  HPLC columns [Kinetex 1 
pentafluorophenol (PFP) reverse phase (RP) (2.6 µm, 100 × 4.6 mm, 100 Å), Synergi Max 2 
RP (4 µm, 250 × 4.6 mm, 80 Å), Luna C18 (2) RP (4 µm, 250 × 4.6 mm, 100 Å), Synergi 3 
Polar RP (4 µm, 250 × 4.6 mm, 80 Å)] and SecurityGuard® cartridges (PFP and C18, 4 × 2.0 4 
mm) were purchased from Phenomenex (Macclesfield, UK). The Eclipse XDB-C18 HPLC (5 5 
µm, 150 × 4.6 mm, 80 Å) column and Bond Elute C18 SPE cartridges (20 mL, 5 g, 70 Å) 6 
were from Agilent (Wokingham, UK). HPLC grade methanol and acetonitrile were 7 
purchased from Fisher Scientific (Loughborough, UK). All water utilized was of Milli-Q 8 
grade (18.2 MΩ cm-1). Sterile filtered human male serum was from AB plasma, Discovery® 9 
DSC-18 SPE cartridges (6 mL, 1 g) and Acrodisc PTFE syringe filters (13 mm, 0.45 µm) 10 
were purchased from Sigma-Aldrich (Dorset, UK). Human feces and urine were collected 11 
following internal protocols, approved by the Norfolk Research Ethics Committee (Norfolk, 12 
UK). A complete list of all analytical standards and their makeup is provided in the 13 
supplementary materials. 14 
 15 
Metabolite modeling 16 
Target compounds for method development were chosen based on previously published 17 
studies and known phase II conjugation pathways and colonic metabolism of other similarly 18 
structured flavonoids. Further details of the modeling protocol are provided in the 19 
supplemental materials. Of the modeled compounds, 35 were commercially available and ten 20 
were chosen for synthesis 29 and utilized in the present study (Supplementary Information 21 
Table 1).  22 
 23 
HPLC-MS/MS conditions 24 
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HPLC-MS/MS analysis was conducted using an Agilent 1200 series HPLC-DAD 1 
(Wokingham, UK), attached to an ABSciex 3200 series Q-trap MS/MS (Warrington, UK), as 2 
described in detail in the supplementary information. The final HPLC-MS/MS analysis 3 
utilized a mobile phase consisting of 0.1% formic acid (v/v) in water and 0.1% formic acid 4 
(v/v) in acetonitrile, with ion spray voltage (IS) -4000 V/+5500 V and temperature 700ºC. 5 
Optimized MRM parameters were established for each analyte with the final method 6 
analyzed separately in both positive and negative ionization mode.  7 
 8 
SPE conditions 9 
The SPE procedure was conducted as described in detail in the supplementary information. 10 
Briefly, the final SPE method consisted of samples being loaded onto either DSC-18 (6 mL, 1 11 
g, urine), Strata-X™ (6 mL, 500 mg, serum) or Bond Elute C18 (20 mL, 5 g, feces) SPE 12 
cartridges, washed with two column volumes of 1% formic acid in water, eluted under 13 
gravity with 1% formic acid in methanol and concentrated using a Speedvac® centrifugal 14 
evaporator.  15 
 16 
Method Validation  17 
Validation of the HPLC-MS/MS method was carried out in terms of the linearity, precision 18 
and accuracy of compounds spiked into mobile phase, using the guidelines set out by the 19 
FDA for Bioanalytical methods validation (2001) 18. LODs were established by calculating 20 
the concentration of analyte yielding a peak height signal-to-noise ratio of 3:1 (signal-to-21 
noise method) when the analyte was spiked into urine, serum and fecal matrices post 22 
extraction. Where the analytes of interest were endogenously present in the fasting urine, 23 
serum or fecal samples, peak heights were corrected for the endogenous analyte 24 
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concentration. All data are given as mean ± SD of three replicates and where stated, statistical 1 
comparisons were undertaken using t-tests (p<0.05, n=3) in SPSS 18 (IBM, UK). 2 
The extraction methods were validated by calculating the extraction efficiencies of the 3 
standards spiked in urine, serum and fecal homogenates prior to SPE, relative to matrix-4 
matched (urine, serum, feces) control samples spiked with the same mixture of the standards 5 
post SPE.  6 
The final urine and plasma methods were applied to samples derived from a previous 7 
clinical intervention trial feeding participants (n=15) a 500 mg bolus of elderberry derived 8 
anthocyanins, where samples were collected for 3 hours post bolus30. The fecal method was 9 
applied to samples derived from a study feeding participants (n=8) a 500 mg bolus dose of 10 
pure 13C-labelled cyanidin-3-glucoside, where samples were collected for 48 hours post 11 
bolus4. The analytes were quantified using the optimized extraction and detection methods 12 
and the lowest and highest urinary, plasma and fecal concentrations identified are presented.  13 
 14 
Results 15 
HPLC-MS/MS 16 
Five HPLC columns commonly utilized in flavonoid analysis (Eclipse XDB C18, Kinetex 17 
PFP, Synergi Max, Luna C18 and Synergi Polar) were selected to establish the 18 
chromatographic separation of the target compounds.  Here, the PFP column provided the 19 
optimal peak resolution, where flow rate was optimal at 1.5 mL min-1 (40% reduced peak 20 
width relative to 1 mL min-1; data not shown). The Eclipse and Luna C18 columns resulted in 21 
poor resolution and separation of the sulfated compounds. Whilst the Synergi Max and 22 
Synergi Polar columns resulted in slightly improved separation, the PFP column provided the 23 
greatest resolution, with a two to tenfold improvement in peak intensity relative to the other 24 
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stationary phases (data not shown). No column tested was capable of sufficiently separating 1 
the isomers of protocatechuic acid (PCA)-sulfate under the explored conditions. 2 
A flow rate of 1.5 mL min-1 decreasing to 1 mL min-1 from 7 to 14 min achieved optimal 3 
separation while staying within the pressure limitations of the HPLC system utilized (<400 4 
bar) and there was no apparent difference in ion intensity when comparing mobile phase 5 
solvents methanol relative to acetonitrile, however, acetonitrile slightly improved the 6 
separation of the analytes at 0.1% formic acid (data not shown). Optimized source parameters 7 
were established at a curtain gas (CUR) of 40 psi, which prevented solvent entering the 8 
orifice, a temperature of 700 °C and gas flows of 60 psi (nebulizer and auxiliary gas) for 9 
optimal nebulization of the solvent. The MRM related parameters, were optimized for each 10 
individual compound separately (Supplementary Information Table 2) and MRM analysis 11 
of the mixed standards at 50 µM was used to verify the final parameters in positive and 12 
negative mode (Figure 1). 13 
The final HPLC-MS/MS method was validated for linearity, precision and accuracy using 14 
six-point calibration curves constructed in 5% methanol, 0.1% formic acid (aqueous), 15 
following six repeat injections. All calibration curves were linear over the concentration 16 
ranges (1.25 to 20 µM) (Table 1) and the HPLC-MS/MS LODs ranged from 1 nM for 17 
phloridzin to 2604 nM for homovanillic acid in urine, 0.3 nM for phloridzin to 2340 nM for 18 
homovanillic acid in serum and 1 nM for phloridzin to 2238 nM for 4-hydroxyphenylacetic 19 
acid in feces (Table 1). 20 
 21 
Extraction 22 
The addition of a preservative (10% ascorbate w/v in 0.5 mM EDTA) prior to SPE and the 23 
change of acid modifier from formic acid to HCl during SPE had little impact on recovery 24 
(p>0.05, n=3; data not shown). The lowest elution volume which provided the maximum 25 
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retention of a range of representative analytes was 7 mL and complete evaporation of the 1 
eluent to dryness reduced the recovery of some compounds significantly (including 2 
anthocyanins and phloroglucinaldehyde (PGA); data not shown). Therefore, samples were 3 
dried to approximately 50 µL, reconstituted with 200 µL acidified water and a volume 4 
marker (scopoletin) was added to allow calculation of the exact volume.  5 
Following solid phase extraction, the mean recovery of the 45 analytes from urine, serum 6 
and feces was 88.3 ± 17.8%, 86.5 ± 11.1% and 80.6 ± 20.9% respectively (Table 2). Of the 7 
total 45 analytes, 34, 34, and 26 compounds were recovered with greater than 80% efficiency 8 
in urine, serum and feces, respectively. Poor recoveries (<50%) were exhibited for 4-9 
methoxysalicyclic acid, gallic acid and benzoic acid (BA)-4-glucuronide in the feces, whilst 10 
the extraction efficiencies of the analytes within urine and serum matrices were all >60% 11 
(Table 2). The coefficient of variation (CV) of the extraction efficiency of the analytes 12 
averaged 7.9 ± 5.3% for urine, 6.8 ± 5.0% for serum and 14.1 ± 7.9% for feces. 13 
 14 
Validation using human samples. 15 
Thirty six of the 45 putative metabolites were detected in the human samples; 26 within 16 
urine, 25 within plasma and 24 with feces, with the minimum concentrations identified 17 
ranging from 0.4 nM for vanillic acid (VA)-sulfate to 127,899 nM for hippuric acid in urine, 18 
2 nM for methyl-3,4-dihydroxybenzoate to 5,771 nM for hippuric acid in plasma and 0.3 nM 19 
for BA-4-glucuronide to 6,974 nM for 2,3-dihydroxyBA in feces (Table 3). The maximum 20 
concentrations identified within participant samples ranged from 3,103,601 nM in urine to 21 
10,106 nM in plasma for hippuric acid and 211,194 nM for ferulic acid in feces. 22 
 23 
Discussion 24 
The objective of the present study was to develop methods suitable for establishing the 25 
ADME of anthocyanins, including the clearance of their degradation products and 26 
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metabolites. The investigation strategy was to: (1) model putative metabolites of 1 
anthocyanins to establish a range of targets for method validation; (2) synthesize glucuronide 2 
and sulfate conjugates of common anthocyanin degradation products; and (3) establish fit for 3 
purpose methods for extracting and quantifying the anthocyanin metabolites. 4 
Achieving suitable chromatographic separation is challenging when large mixtures of 5 
analytes are present in a complex matrix and is further complicated by the presence of 6 
isomers (e.g: PCA-3-sulfate, PCA-4-sulfate). The five columns described in the present study 7 
were selected for analysis based on their frequent use within flavonoid research31-34. The 8 
majority of studies using RP-HPLC to analyse anthocyanins have utilised C18 packing 9 
materials31-34. However, more recently interest has grown in newer Kinetex phases such as 10 
the PFP stationary phase, which incorporates fluorine atoms on the periphery of a phenyl ring. 11 
This enables chromatographic separation via dipole-dipole interactions, hydrogen bonding 12 
and π- π interactions in addition to the hydrophobic and shape selectivity retention 13 
mechanisms utilised by more typical C18 columns35. Of the five HPLC columns tested, the 14 
present study identified the Kinetex PFP column as providing the greatest chromatographic 15 
separation efficiency under the present conditions and also demonstrated superior resolution 16 
of the sulfated conjugates. None of the columns tested were able to effectively separate the 17 
isomers of PCA sulfate under the explored conditions. In addition, changing the mobile phase 18 
from methanol to acetonitrile and decreasing the flow rate to 1 mL min-1 from 7 to 14 min 19 
within the run-time significantly improved the separation. A column temperature of 37 °C 20 
was selected to reduce the system backpressure, whilst staying within a physiologically 21 
relevant temperature range for these analytes as their stability is uncertain at higher 22 
temperatures. A high source temperature (700 °C) and gas flow (60 psi) appeared particularly 23 
important to ensure ionization of the compounds at this relatively high flow rate. It should be 24 
noted that HPLC and MS optimization is instrument specific and the presented values (Table 25 
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2) should only be used as a guide for method development or validation, with lower flow 1 
rates likely proving optimal with other instruments and column dimensions. An 2 
unconventional HPLC method, where the flow rate was decreased from 1.5 mL/min to 1 3 
mL/min from 7 to 14 min was selected for use in the current study, as it enabled optimal 4 
separation of isomeric compounds eluting within this timeframe. 5 
The LODs of the final method ranged from 0.3 nM (for phloridzin in serum) to 2604 nM 6 
(for homoVA in urine) (Table 1). The LODs of the majority of the compounds were below 7 
100 nM; however, the LODs of 8, 7 and 15 compounds in urine, serum and feces respectively 8 
were above 100 nM, generally a result of a high ‘baseline noise’ (background mass spectrum) 9 
or poor ionization. The LOD for homoVA was extremely high as a result of its high fasting 10 
endogenous analyte concentration and poor ionization; suggesting the described HPLC-11 
MS/MS method is not optimal for the detection of low levels of the metabolite in biological 12 
samples. Yet despite this, it was still quantifiable, as it was present at such high 13 
concentrations within urine. In these cases where ionization is poor, derivatization and 14 
quantification via GC-MS should be considered. Furthermore, the goal of the present study 15 
was to develop a single method for detecting an extensive range of anthocyanins and phenolic 16 
metabolites within a single HPLC-MS method and mobile phase, for the processing of large 17 
numbers of clinical samples. Sensitivity could be improved for certain analytes, by 18 
optimizing flow rates, mobile phases and source parameters separately for anthocyanins, 19 
phenolic acids, and polar phenolic metabolites. However this would require multiple methods 20 
and mobile phases. For example, increasing the acid content of the mobile phase would 21 
improve the chromatographic resolution of anthocyanins, but this would have deleterious 22 
effects on the ionisation of other analytes.SPE is often the preferred extraction method when 23 
utilizing HPLC-MS/MS as it removes salts that may affect ionization 36. It should be noted 24 
however that dilution, acidification and syringe filtration 23-25, protein precipitation 22-25,27,37 25 
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and liquid-liquid extraction 27,28 are also often commonly used techniques in the analysis of 1 
polyphenols 23-25. These methods were also initially and exhaustively explored, however, due 2 
to issues with poor recovery, extremely high variability (inter- and intra-extraction) and 3 
insufficient chromatographic resolution of some analytes (data not shown), they were 4 
abandoned in favor of SPE. Thus, SPE was the optimal method for the extraction of 5 
anthocyanin metabolites, resulting in mean extraction efficiencies of 88.3 ± 17.8% for urine, 6 
86.5 ± 11.1% for serum and 80.6 ± 20.9% for feces for the 45 modeled metabolites. In 7 
addition, the methods provided acceptable reproducibility for the established extraction 8 
efficiencies (Table 2). For urine extraction, the DSC-18 and Strata-X™ SPE cartridges 9 
yielded similar recoveries for C3G, PGA and the internal standard (taxifolin), however the 10 
binding characteristics of the polymeric divinylbenzene Strata-X™ sorbent allowed large 11 
amounts of polar compounds in the matrix to remain bound to the column after the aqueous 12 
wash, resulting in poor resolution of PCA and PCA-4-glucuronide from other analytes when 13 
using UVvis detection. Therefore, DSC-18 SPE cartridges, were selected as they gave 14 
superior recoveries for compounds from urine. However, when using MRM as a single 15 
detection method, co-elution of background analytes may be of limited significance, thus 16 
permitting the use of Strata-X™. Within serum, the more selective Strata-X™ cartridges 17 
were optimal for the extraction of target analytes, as they afforded higher extraction 18 
efficiencies and improved repeatability under the explored conditions. The SPE recoveries of 19 
the 45 analytes of interest ranged from 10.2 ± 4.6% to 121 ± 41.5% with a high mean 20 
recovery of 80.6 ± 20.9%, demonstrating that despite the complexity of the fecal matrix, the 21 
presented method is suitable for the recovery of the target analytes.  22 
Validation of the methods for use with clinical samples 4,30, was carried out using matrix-23 
matched standard curves rather than standard curves prepared in mobile phase (a common 24 
approach), which provides an extra degree of precision as the ionization efficiencies of the 25 
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sample and standards are more similar compared to using mobile phase alone. The methods 1 
described herein were successful in identifying 36 metabolites, 26 analytes within urine, 25 2 
within serum, and 24 within feces; 19 of which have now been confirmed as anthocyanin 3 
metabolites in a recent 13C-labelled anthocyanin study 4. The lowest concentrations of the 4 
metabolites identified in the urine samples ranged from 0.4 nM for VA-4-sulfate to 127,899 5 
nM for hippuric acid, while concentrations in the plasma ranged from 2 nM for methyl-3,4-6 
dihydroxybenzoate to 5,771 nM for hippuric acid and concentrations in the feces ranged from 7 
0.3 nM for BA-4-glucuronide to 6,974 nM for 2,3-dihydroxyBA (Table 3). The identification 8 
of these metabolites within clinical samples demonstrates that the methods are suitable and 9 
have acceptable LODs for the detection of anthocyanin metabolites in clinically relevant 10 
samples.  11 
 12 
Conclusion 13 
The present study describes the validation of analytical methods that are suitable for the 14 
quantification of a large number of structurally diverse anthocyanin metabolites, thus 15 
providing a valuable tool for future studies of ADME and bioactivity.  16 
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Supporting Information Available  1 
Supporting information containing a list of all analytical standards, their structures and 2 
makeup and a complete description of the analytical methods, including the optimized MRM 3 
parameters is provided. This information is available free of charge via the Internet at 4 
http://pubs.acs.org/. 5 
 6 
ABBREVIATIONS 7 
C3G, cyanidin-3-glucoside; LLE, liquid-liquid extraction; ADME, absorption distribution 8 
metabolism elimination;  DMSO, dimethyl sulfoxide; PCA, protocatechuic acid;  PGA, 9 
phloroglucinaldehyde; PFP, pentafluorophenyl; RP, reverse phase; SPE, solid phase 10 
extraction; MRM, multiple reaction monitoring; DP, declustering potential; EP, entrance 11 
potential; CE, collision energy; CXP, collision exit potential; CUR, curtain gas; CV, 12 
coefficient of variation; LOD, limit of detection. 13 
Figure 1. Multiple reaction monitoring (MRM) chromatogram of standard compounds, 14 
illustrating optimized negative (A) and positive (B) HPLC-MS/MS methods. (A) 1Gallic acid, 15 
2Benzoic acid (BA)-4-glucuronide, 3PCA-4-glucuronide, 4PCA-3-glucuronide, 5Vanillic acid-16 
4-glucuronide, 6Protocatechuic acid (PCA),73,5-DihydroxyBA, 8PCA-3 and 4-sulfate, 94-17 
Hydroxybenzyl alcohol, 10Homoprotocatechuic acid, 11Isovanillic acid-3-glucuronide, 12BA-18 
4-sulfate, 133,4-Dihydroxybenzaldehyde, 14Isovanillic acid-3-sulfate, 154-HydroxyBA, 19 
16Hippuric acid, 174-Hydroxyphenylacetic acid, 18Vanillic acid-4-sulfate, 19Methylgallate, 203-20 
HydroxyBA, 212,3-DihydroxyBA, 224-Hydroxybenzaldehyde, 23Vanillic acid (VA), 242,4-21 
DihydroxyBA, 25Homovanillic acid, 26Caffeic acid, 277,8-Dihydroxycourmarin, 284-22 
Methylhippuric acid, 29Methyl 3,4-dihydroxybenzoate, 303-Methylhippuric acid, 31p-23 
15 
 
Coumaric acid, 32Phloroglucinaldehyde, 33Ferulic acid, 342-HydroxyBA, 35Sinapic acid, 1 
36Taxifolin, 374-Methoxysalicylic acid, 386-Methoxysalicyclic acid, 39Phloridzin. (B) 13-2 
Methylgallic acid, 2Isovanillic acid, 3Cyanidin-3-glucoside, 4Syringic acid, 52-MethoxyBA, 3 
6Pelargonidin-3-glucoside, 7Methyl vanillate, 8Methyl-3,4-dimethoxybenzoate. 4 
16 
 
Table 1. Precision data and limits of detection for the optimized urine, serum and fecal methods. 1 
Analyte 
Ionization 
Mode 
Slope (a)a 
Mean ± SD 
CV 
(%) 
R² 
LOD (nM) 
Urine Serum Feces 
Cyanidin-3-glucoside + 594,473 ± 39,888 6.71 0.998 2 4 4 
Pelargonidin-3-glucoside + 1,034,231 ± 98,822 9.56 0.996 2 1 2 
2-Hydroxybenzoic acid - 189,231 ± 4334 2.29 0.998 116 86 136 
3-Hydroxybenzoic acid - 60,138 ± 2698 4.49 0.999 173 191 214 
4-Hydroxybenzoic acid - 167,981 ± 7078 4.21 0.995 139 74 86 
2,3-Dihydroxybenzoic acid - 78,108 ± 1819 2.33 0.999 92 29 126 
2,4-Dihydroxybenzoic acid - 19,681 ± 746 3.79 0.999 98 68 112 
Protocatechuic acid (PCA) - 15,128 ± 760 5.02 0.997 41 1 9 
PCA-3-glucuronide - 174,408 ± 5711 3.27 0.999 6 1 4 
PCA-4-glucuronide - 102,003 ± 4943 4.85 0.999 5 2 4 
PCA-3 and 4-sulfate - 378,495 ± 13,989 3.70 0.998 1 2 1 
3,5-Dihydroxybenzoic acid - 234,649 ± 8897 3.79 0.996 24 31 150 
Gallic acid - 34,012 ± 907 2.67 0.997 15 29 20 
2-Methoxybenzoic acid + 400,431 ± 20,139 5.03 0.996 16 23 22 
4-Methoxysalicylic acid - 300,116 ± 9224 3.07 0.998 23 29 375 
6-Methoxysalicyclic acid - 15,687 ± 583 3.72 0.999 116 25 333 
Vanillic acid (VA) - 11,322 ± 337 2.97 0.999 53 16 45 
VA-4-glucuronide - 56,069 ± 2416 4.31 0.999 37 6 11 
VA-4-sulfate  - 214,295 ± 3041 1.42 0.999 2 3 3 
IsoVA + 30,715 ± 1362 4.44 0.998 47 77 94 
IsoVA-3-glucuronide - 67,871 ± 3294 4.85 1.000 9 5 9 
IsoVA-3-sulfate - 308,646 ± 7864 2.55 0.999 2 3 3 
Syringic acid + 61,287 ± 2709 4.42 0.998 16 45 21 
3-Methylgallic acid - 1584 ± 69 4.37 0.997 360 121 400 
Benzoic acid-4-glucuronide  - 66,978 ± 2529 3.78 0.998 4 10 21 
Benzoic acid-4-sulfate  - 143,079 ± 4552 3.18 0.998 1 4 2 
Methyl-3,4-dihydroxybenzoate - 230,527 ± 10,659 4.62 0.996 2 3 6 
Methyl-3,4-dimethoxybenzoate + 93,306 ± 5946 6.37 0.999 8 23 22 
Methyl vanillate + 33,814 ± 3204 9.47 0.999 43 68 36 
Methyl gallate - 257,934 ± 19,070 7.39 1.00 1 2 3 
4-Hydroxybenzyl alcohol - 963 ± 40 4.16 0.995 62 246 424 
p-Coumaric acid - 111,853 ± 8169 7.30 0.994 46 51 30 
Caffeic acid - 333,099 ± 8610 2.58 0.992 67 122 100 
Ferulic acid - 40,588 ± 1939 4.78 1.000 14 9 67 
Sinapic acid - 7806 ± 638 8.17 0.999 39 7 20 
Phloroglucinaldehyde  - 23,907 ± 1126 4.71 0.992 13 5 40 
4-Hydroxybenzaldehyde - 1235 ± 63 5.11 0.998 25 40 14 
17 
 
3,4-Dihydroxybenzaldehyde - 43,960 ± 1288 2.93 0.993 10 4 2 
4-Hydroxyphenylacetic acid - 30,535 ± 1017 3.33 0.998 116 938 2238 
HomoPCA - 2146 ± 65 3.03 0.999 108 117 413 
HomoVA - 23,907 ± 1126 4.71 0.992 2604 2340 727 
Hippuric acid - 92,688 ± 3528 3.81 0.996 4 0.4 70 
3-Methylhippuric acid - 160,138 ± 5016 3.13 0.999 99 43 105 
4-Methylhippuric acid - 99,126 ± 4512 4.55 0.999 77 43 122 
 Internal standards 
Phloridzin - 292,333 ± 6420 2.20 0.991 1 0.3 1 
Scopoletin - 10,817 ± 536 4.96 0.999 23 11 30 
Taxifolin - 124,601 ± 3176 2.55 0.995 5 5 6 
7,8-Dihydroxycourmarin - 28,696 ± 1308 4.56 0.994 19 20 3 
aLinear regression analysis with a regression equation of y = ax + b, where x is the concentration in 1 
µM, b is equal to 0 and y is the peak area; LOD, the limit of detection (Signal/Noise = 3); R2, 2 
correlation coefficient of regression equations.  3 
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Table 2. SPE extraction efficiencies of analytes in urine, serum and faecal matrices as 1 
determined using HPLC-ESI-MS/MS. 2 
Analyte 
Extraction Efficiency (% recovery) 
Urine Serum Faeces 
Cyanidin-3-glucoside 97.8 ± 6.2 72.1 ± 4.6 55.4 ± 9.0 
Pelargonidin-3-glucoside 101.9 ± 6.0 74.0 ± 3.4 64.5 ± 11.0 
2-Hydroxybenzoic acid 89.6 ± 1.1 81.2 ± 3.0 71.2 ± 7.0 
3-Hydroxybenzoic acid 85.8 ± 10.5 92.9 ± 7.6 82.9 ± 10.1 
4-Hydroxybenzoic acid 86.2 ± 2.0 86.6 ± 9.8 121.1 ± 41.5 
2,3-Dihydroxybenzoic acid 86.8 ± 3.0 73.9 ± 4.4 86.6 ± 7.8 
2,4-Dihydroxybenzoic acid 79.1 ± 10.0 97.4 ± 3.0 79.9 ± 6.4 
Protocatechuic acid (PCA) 89.7 ± 10.7 89.3 ± 6.4 80.4 ± 4.3 
PCA-3-glucuronide 94.9 ± 5.0 92.0 ± 6.3 78.4 ± 5.8 
PCA-4-glucuronide 91.8 ± 5.1 93.2 ± 1.3 84.8 ± 23.4 
PCA-3 and 4-sulfate 92.9 ± 1.9 67.4 ± 11.5 111.0 ± 13.6 
3,5-Dihydroxybenzoic acid 91.3 ± 16.9 80.9 ± 16.7 82.0 ± 13.7 
Gallic acid 72.8 ± 3.9 85.0 ± 7.6 10.2 ± 4.6 
2-Methoxybenzoic acid 90.6 ± 3.5 89.6 ± 6.3 93.7 ± 10.9 
4-Methoxysalicylic acid 92.7 ± 2.2 85.3 ± 3.6 9.3 ± 2.7 
6-Methoxysalicyclic acid 95.9 ± 1.9 85.3 ± 3.1 67.7 ± 3.0 
Vanillic acid (VA) 91.6 ± 3.9 87.3 ± 3.7 76.0 ± 8.2 
VA-4-glucuronide 74.5 ± 12.8 93.6 ± 2.6 85.9 ± 12.8 
VA-4-sulfate  87.3 ± 7.1 92.6 ± 2.6 96.2 ± 16.8 
IsoVA 110.7 ± 10.2 101.8 ± 5.8 79.4 ± 11.6 
IsoVA-3-glucuronide 89.6 ± 5.0 86.7 ± 12.0 76.6 ± 8.2 
IsoVA-3-sulfate 96.2 ± 6.3 92.6 ± 9.3 84.2 ± 13.0 
Syringic acid 104.5 ± 8.3 87.7 ± 2.6 82.7 ± 4.7 
3-Methylgallic acid 79.6 ± 17.4 95.3 ± 3.7 75.2 ± 3.8 
Benzoic acid-4-glucuronide  85.8 ± 1.9 103.5 ± 5.6 42.0 ± 11.6 
Benzoic acid-4-sulfate  77.3 ± 7.1 94.2 ± 3.3 89.6 ± 15.3 
Methyl-3,4-dihydroxybenzoate 87.2 ± 9.4 82.6 ± 17.8 79.2 ± 6.1 
Methyl-3,4-dimethoxybenzoate 96.8 ± 3.9 73.3 ± 3.2 73.0 ± 7.2 
Methyl vanillate 101.5 ± 11.8 83.6 ± 2.1 80.9 ± 13.6 
Methyl gallate 87.7 ± 13.0 64.9 ± 5.3 101.4 ± 23.0 
4-Hydroxybenzyl alcohol 72.9 ± 8.7 80.0 ± 3.9 92.7 ± 12.2 
p-Coumaric acid 93.5 ± 10.2 88.1 ± 6.0 87.6 ± 9.4 
Caffeic acid 78.6 ± 9.1 75.7 ± 6.0 98.6 ± 12.8 
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Ferulic acid 105.3 ± 2.1 100.0 ± 4.4 74.3 ± 6.8 
Sinapic acid 110.1 ± 5.6 88.7 ± 0.5 79.6 ± 9.8 
Phloroglucinaldehyde  64.5 ± 5.9 79.7 ± 8.4 66.4 ± 7.0 
4-Hydroxybenzaldehyde 85.8 ± 8.7 73.7 ± 6.1 97.0 ± 13.4 
3,4-Dihydroxybenzaldehyde 77.8 ± 7.9 83.8 ± 9.2 109.4 ± 26.8 
4-Hydroxyphenylacetic acid 87.2 ± 2.8 87.6 ± 7.9 82.1 ± 19.9 
HomoPCA 60.0 ± 11.6 72.0 ± 3.2 88.2 ± 11.8 
HomoVA 81.9 ± 9.7 107.3 ± 1.1 63.4 ± 7.3 
Hippuric acid NQa 98.9 ± 2.4 87.3 ± 11.5 
3-Methylhippuric acid 76.6 ± 9.6 95.4 ± 0.4 85.4 ± 10.5 
4-Methylhippuric acid 92.5 ± 1.7 90.3 ± 6.2 77.1 ± 6.2 
Internal standards 
Phloridzin 81.6 ± 6.4 77.2 ± 15.0 75.5 ± 7.4 
Scopoletinb VC VC VC 
Taxifolin 96.6 ± 0.9 88.6 ± 4.4 76.6 ± 11.0 
7,8-Dihydroxycourmarin 88.8 ± 0.8 87.5 ± 5.4 98.0 ± 12.5 
Extraction efficiencies are expressed as mean % ± SD using DSC-18, Strata-X and 1 
Bond Elute C18 SPE cartridges for the extraction of urine, serum and fecal matrices 2 
respectively; VC, volume control; aNQ, not quantified due to high background 3 
concentrations in urine; bScopoletin was used as a volume control standard and was 4 
therefore added post extraction only. 5 
 6 
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Table 3. Minimum and maximum concentrations of analytes detected in spot urine, serum and fecal 1 
samples post consumption of 500 mg anthocyanins. 2 
Analyte 
Urine (nM) Serum (nM) Faeces (nM) 
Mina Maxb Mina Maxb Minc Maxd 
Cyanidin-3-glucoside 2 6348 4 7 2017 2017 
2-Hydroxybenzoic acid 37 2919 173 211 ND ND 
3-Hydroxybenzoic acid 60 21,024 21 36 ND ND 
4-Hydroxybenzoic acid 656 9892 30 39 34 3,026 
2,3-Dihydroxybenzoic acid 12 12,360 ND ND 6974 21,044 
Protocatechuic acid (PCA) 31 8117 11 24 8 33,081 
PCA-3-glucuronide 2 8161 3 15 20 713 
PCA-4-glucuronide 7 2771 4 14 9 1,127 
PCA-3 and 4-sulfate 14 29,403 734 358 2 872 
3,5-Dihydroxybenzoic acid 134 21,328 18 50 ND ND 
4-Methoxysalicylic acid ND ND 0.3 2 29 11,420 
Vanillic acid (VA) 66 18,076 6 62 282 16,663 
VA-4-glucuronide 74 18,929 16 120 29 285 
VA-4-sulfate  0.4 75,259 23 161 0.3 1968 
IsoVA ND ND ND ND 177 230 
IsoVA-3-glucuronide 4 15,680 10 24 18 241 
IsoVA-3-sulfate 0.4 75,259 23 161 1 4993 
Syringic acid ND ND 5 22 ND ND 
Benzoic acid-4-glucuronide  3 623 7 10 0.3 1477 
Benzoic acid-4-sulfate  ND ND 66 196 ND ND 
Methyl-3,4-dihydroxybenzoate ND ND 2 6 58 7425 
Methyl gallate ND ND 3 5 ND ND 
Methyl vanillate ND ND ND ND 2726 2726 
4-Hydroxybenzyl alcohol 228 17,663 ND ND ND ND 
p-Coumaric acid 13 3040 ND ND ND ND 
Caffeic acid ND ND ND ND 4168 9285 
Ferulic acid 15 9908 7.7 28 131 211,194 
Sinapic acid 5 8842 ND ND ND ND 
Phloroglucinaldehyde  7 3477 4 103 10 11,216 
4-Hydroxybenzaldehyde ND ND 97 182 9 105 
3,4-Dihydroxybenzaldehyde ND ND 17 23 11 724 
HomoPCA 309 22,045 ND ND 8 1879 
HomoVA 1493 289,697 ND ND ND ND 
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Hippuric acid 127,899 3,102,601 5771 10,106 13 748 
3-Methylhippuric acid 29 5831 ND ND ND ND 
4-Methylhippuric acid 16 2963 ND ND ND ND 
ND, not detected; aAbsolute minimum and bmaximum analyte concentration detected within fasting 1 
pre bolus and 1, 2 and 3 hours post bolus spot urine and serum samples of 15 participants fed 500 mg 2 
elderberry anthocyanins 5,30; cAbsolute minimum and dmaximum analyte concentration detected within 3 
8 participants fed 500 mg 13C-labelled cyanidin-3-glucoside, where samples were collected for 48 4 
hours post bolus 4. 5 
  6 
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